The Tuberculosis Drug Accelerator at year 10: what have we learned?

Lgenia’s Chief Executive Officer and Chief Scientific Officer, Dr. Philip Hipskind, recently multi-authored the paper “The Tuberculosis Drug Accelerator at year 10: what have we learned?” in the journal Nature Medicine. The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. The paper reviews the consortium’s achievements, advantages, and limitations and advocates for the application of similar models to other diseases. Learn…

Read More

Indiana-based BioTech Collaborates with IU School of Medicine to Help Find a Cure for Alzheimer’s

Indianapolis, Indiana; March 2, 2020 – LGENIA, an Indiana-based biotechnology company which has to date focused on its partnership with the TB Drug Accelerator (sponsored by the Bill and Melinda Gates Foundation) announces today that it will collaborate with the Indiana University School of Medicine to discover new medicines for Alzheimer’s disease. The IU School of Medicine was recently awarded a $36 million grant from the National Institutes of Health to create an Alzheimer’s disease drug discovery center with the…

Read More